Trial of olaparib palbociclib and fulvestrant in patients with BRCA mutation-associated hormone receptor-positive human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer

The main purpose of this research study is to learn whether the investigational combination of olaparib, palbociclib, and fulvestrant is safe in patients with estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+) breast cancer and BRCA1 or BRCA2 mutations.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  breast cancer,metastatic breast cancer
• Age: Between 18 Years - 99 Years
• Gender: All